CMG MedSource Book a Free Call Home›Resources›503A vs. 503B Compounding Compounding Compliance 503A vs. 503B Compounding: What Healthcare Providers Need to Know CMG MedSource September 2026 8 min read If your practice administers or prescribes compounded medications, including GLP-1s, peptides, or hormone therapies, you need to understand the difference between 503A compounding pharmacies and 503B outsourcing facilities. The distinction affects how you can legally obtain compounded medications, what quality standards apply, and what documentation you need to maintain. The Regulatory Framework The terms "503A" and "503B" refer to specific sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Drug Quality and Security Act (DQSA) of 2013. Congress created this framework after a series of high-profile contamination events involving compounded sterile preparations, most notably the 2012 New England Compounding Center meningitis outbreak that killed 64 people. The result was a two-tiered regulatory structure: a traditional track (503A) for patient-specific compounding by licensed pharmacies, and a new FDA-registered track (503B) for larger-scale compounding operations that supply healthcare providers directly. 503A Compounding Pharmacies A 503A pharmacy operates under state pharmacy board regulation and must have a valid patient prescription before dispensing a compounded medication. This is the traditional model most providers have worked with for decades. Regulated primarily by state pharmacy boards Requires a patient-specific prescription before compounding or dispensing Cannot compound anticipatory or speculative amounts for office stock Must follow USP compounding standards (USP 795, USP 797 for sterile preparations) Subject to state inspection, not routine FDA inspection Can compound medications that are commercially available under certain conditions 503B Outsourcing Facilities A 503B outsourcing facility is voluntarily registered with the FDA and subject to federal inspection under CGMP (Current Good Manufacturing Practice) standards. This higher level of oversight is what allows them to operate differently from a traditional pharmacy. Voluntarily registered with and inspected by the FDA Must comply with CGMP manufacturing standards (similar requirements to pharmaceutical manufacturers) Can compound medications without individual patient prescriptions Can distribute compounded medications directly to licensed healthcare facilities for office use Subject to lot-release testing and stricter documentation requirements Typically offer sterility-tested, batch-released products with longer beyond-use dates Key distinction for clinic operators: A 503B facility allows your practice to stock a compounded medication for administration to patients without requiring a prescription at the point of purchase. You obtain the medication, then prescribe it for each patient. With a 503A pharmacy, the prescription must come first. Side-by-Side Comparison Factor 503A Pharmacy 503B Outsourcing Facility Regulatory body State pharmacy board FDA (CGMP oversight) Prescription required Yes, before compounding No, for office stock orders Distribution Directly to patients To licensed healthcare facilities Batch compounding Limited anticipatory quantities Large-scale batch production permitted Quality standards USP 795 / USP 797 CGMP (21 CFR Parts 210/211) Sterility testing Varies by state and product Required for sterile preparations Best suited for Individual patient customizations Multi-patient office stock, clinics Which Type Does Your Practice Need? Most medical practices administering medications to multiple patients, including medical spas, telehealth operators, longevity clinics, and weight management practices, work primarily with 503B outsourcing facilities. The ability to stock medications for office use without requiring an individual prescription for each order simplifies the supply chain considerably. 503A pharmacies remain essential when a patient requires a customized formulation, such as a specific dosage strength not available from a 503B facility, a particular base or diluent for patient tolerance, or a unique combination product. Many practices use both: a 503B facility for standard office stock and a 503A pharmacy for patient-specific customizations. Common Misconceptions Misconception: 503B medications are FDA-approved 503B facilities are FDA-registered and inspected, but the compounded medications they produce are not FDA-approved drug products. The FDA approves manufacturing facilities and processes, not individual compounded preparations. This is an important distinction to communicate to patients. Misconception: 503A pharmacies are lower quality 503A pharmacies can compound high-quality medications under USP standards, and many have excellent track records. The quality distinction depends more on the individual pharmacy's practices than on the regulatory classification alone. Both 503A and 503B facilities can produce safe, effective compounded medications when operating compliantly. Misconception: You need a pharmacy license to order from 503B facilities Licensed healthcare practitioners and facilities (physicians, nurse practitioners, physician assistants, clinics, and hospitals) can order directly from 503B outsourcing facilities without holding a pharmacy license. You do need a valid DEA registration for controlled substances and must meet the facility's credentialing requirements. Frequently Asked Questions What is a 503A compounding pharmacy? A 503A compounding pharmacy is a state-licensed pharmacy that compounds medications for individual patients based on a valid prescription from a licensed prescriber. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and are regulated primarily by state pharmacy boards. Medications cannot be dispensed without a patient-specific prescription. What is a 503B outsourcing facility? A 503B outsourcing facility is a compounding operation voluntarily registered with the FDA that can produce large batches of compounded medications without individual patient prescriptions. They must comply with CGMP manufacturing standards and can distribute compounded medications directly to licensed healthcare providers for office use. Can I order from a 503B facility for my medical spa or clinic? Yes. Licensed healthcare providers and licensed facilities can order directly from 503B outsourcing facilities. You will need to provide your state license, DEA registration (where applicable), and complete the facility's provider credentialing process. The medication can then be administered to patients under your clinical protocols. How do I find vetted 503B outsourcing facilities? The FDA maintains a public list of registered 503B outsourcing facilities on its website. Beyond the registry, evaluating a facility's inspection history, quality documentation practices, and product availability is important. CMG MedSource works with a vetted network of 503A and 503B facilities and can match your practice with compliant sourcing options based on your clinical needs. Are compounded GLP-1 medications available from 503B facilities? Compounded semaglutide and tirzepatide have been available from both 503A and 503B facilities. Regulatory status for specific compounds changes based on FDA shortage designations and policy decisions. As of late 2025, the FDA ended the shortage designation for semaglutide and tirzepatide, which affects the compounding pathway. Consult with a sourcing partner familiar with current regulatory status before placing orders for GLP-1 compounds. Need Help Navigating Compounding Sourcing? CMG MedSource connects licensed providers with vetted 503A and 503B facilities. Our sourcing consultation is free for licensed providers. Book a Free 15-Minute Call Related articles: GLP-1 Compounding for Medical Practices: A Provider's Guide How Telehealth Providers Source Compounded Medications Compliantly Compounded Peptide Therapy: Sourcing, Compliance, and Clinical Use Home info@cmgmedsource.com Schedule a Call CMG MedSource | Dallas, Texas | Pharmaceutical Sourcing for Licensed Providers This content is for informational purposes only and does not constitute legal or regulatory advice. Consult with a compliance professional for guidance specific to your practice.